A Sequential Dual GLP-1R/GIPR Agonist-To-Antagonist Molecule Achieves Superior Weight Loss in Obese Mice.
BACKGROUND: The GLP-1 receptor (GLP-1R) and GIP receptor (GIPR) are key targets for diabetes and obesity therapies. RESULTS: Our findings revealed that the sequential molecule GLP-1(A8G)/GIP(1-30)-Fc produced the greatest body weight reduction (21.59%), significantly outperforming GLP-1(A8G)/GIP(3-30)-Fc (14.5%; p < 0.001).
BACKGROUND: The GLP-1 receptor (GLP-1R) and GIP receptor (GIPR) are key targets for diabetes and obesity therapies. RESULTS: Our findings revealed that the sequential molecule GLP-1(A8G)/GIP(1-30)-Fc produced the greatest body weight reduction (21.59%), significantly outperforming GLP-1(A8G)/GIP(3-30)-Fc (14.5%; p < 0.001).
What the study was
- Study design
- Preclinical study
- Category
- Prevention
- Maturity
- Exploratory
- Journal
- Diabetes, obesity & metabolism
Why it surfaced
Low-signal Cardiovascular-metabolic: GLP-1, SGLT2, cardiometabolic risk entry (Preclinical study design); retained for topic coverage completeness.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.